Clinical Trials Browser

Phase 2 × Interventional × Hematopoietic Cell Growth Factors × Clear all

NCT00398047 2018-09-06

Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic Syndromes

Phase 2 Terminated

3 enrolled 6 charts

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic